论文部分内容阅读
目的探讨阿托伐他汀联合辅酶Q10治疗冠状动脉粥样硬化性心脏病(CHD)早期心功能减退患者的疗效。方法选取2015年4月至2016年4月汉川市人民医院收治的170例CHD早期心功能减退患者作为研究对象,采用随机数字表法分为对照组和观察组,每组85例。对照组患者采用阿托伐他汀治疗,观察组采用阿托伐他汀联合辅酶Q10治疗,比较两组患者临床疗效、治疗前后心率、血压及心功能改善情况、不良反应发生情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的心率、收缩压和舒张压水平均明显低于对照组,差异均有统计学意义(均P<0.05);治疗后,观察组患者左室舒张末期内径(LVEDD)及左心室收缩末期内径(LVESD)均明显低于对照组,左室射血分数(LVEF)显著高于对照组,差异均有统计学意义(均P<0.05)。结论阿托伐他汀联合辅酶Q10治疗CHD早期心功能减退效果显著,可有效地改善患者血压和心功能,临床不良反应发生率较低。
Objective To investigate the efficacy of atorvastatin combined with coenzyme Q10 in the treatment of patients with early cardiac dysfunction in patients with coronary atherosclerotic heart disease (CHD). Methods From April 2015 to April 2016, 170 CHD patients with early CHD admitted to Hanchuan People’s Hospital were enrolled in this study. They were divided into control group and observation group by random number table. Each group included 85 cases. The patients in the control group were treated with atorvastatin. The patients in the observation group were treated with atorvastatin combined with coenzyme Q10. The clinical efficacy, heart rate, blood pressure and heart function before and after treatment were compared between two groups. The occurrence of adverse reactions were compared. Results The total effective rate of observation group was significantly higher than that of control group (P <0.05). After treatment, heart rate, systolic blood pressure and diastolic blood pressure of observation group were significantly lower than those of control group (LVEDD) and left ventricular end-systolic diameter (LVESD) in the observation group were significantly lower than those in the control group after treatment, and the left ventricular ejection fraction (LVEF) was significant Higher than the control group, the difference was statistically significant (P <0.05). Conclusions Atorvastatin combined with Coenzyme Q10 can significantly reduce the early stage of cardiac dysfunction in patients with CHD. It can effectively improve the blood pressure and heart function in patients with lower incidence of clinical adverse reactions.